LENZ Therapeutics (LENZ) Share-based Compensation (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Share-based Compensation data on file, last reported at $4.3 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 69.04% year-over-year to $4.3 million in Q1 2026; TTM through Mar 2026 was $1.8 million, a 35.24% decrease from a year earlier, with the FY2024 full-year figure at $1.1 million, down 84.92% from the prior year.
• Share-based Compensation for Q1 2026 stood at $4.3 million, up from -$2.6 million in the prior quarter.
• Over the last five years, Share-based Compensation for LENZ reached as high as $9.9 million in Q3 2023 and fell as low as -$3.6 million in Q4 2024.
• Historically, Share-based Compensation has averaged $2.4 million across 5 years, with a median of $3.2 million in 2022.
• Across the five-year window, Share-based Compensation jumped 223.52% in 2022 and plunged 1042.8% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $3.6 million in 2022, then jumped by 173.33% to $9.9 million in 2023, then tumbled by 136.56% to -$3.6 million in 2024, then climbed by 29.4% to -$2.6 million in 2025, then jumped by 269.04% to $4.3 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $4.3 million in Q1 2026, -$2.6 million in Q2 2025, and $2.6 million in Q1 2025.